Global Multiple Sclerosis Market, 2017-2022: Patie

Dublin, Sept. 25, 2017 (GLOBE NEWSWIRE) -- The "Global Multiple Sclerosis Market: Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)" report has been added to Research and Markets' offering.

Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022

Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market. Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country. Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price. Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.

Key Topics Covered:

1. Research Findings 2. Global Multiple Sclerosis Patient Numbers (2011 - 2022) 3. Global Multiple Sclerosis Market (2011 - 2022) 4. Patient Share - Global Multiple Sclerosis (2011 - 2022) 5. Market Share - Global Multiple Sclerosis (2011 - 2022) 6. United Kingdom 7. France 8. Germany 9. Italy 10. Spain 11. United States 12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents) 13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)

For more information about this report visit https://www.researchandmarkets.com/research/5...l_multiple

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Central Nervous System Drugs , Central Nervous System Drugs , Infusions and Injectables